KR20100063088A - 서방성 아지스로마이신 고형 약형 - Google Patents

서방성 아지스로마이신 고형 약형 Download PDF

Info

Publication number
KR20100063088A
KR20100063088A KR1020107006490A KR20107006490A KR20100063088A KR 20100063088 A KR20100063088 A KR 20100063088A KR 1020107006490 A KR1020107006490 A KR 1020107006490A KR 20107006490 A KR20107006490 A KR 20107006490A KR 20100063088 A KR20100063088 A KR 20100063088A
Authority
KR
South Korea
Prior art keywords
azithromycin
dosage form
oral dosage
solid oral
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107006490A
Other languages
English (en)
Korean (ko)
Inventor
라드하크리쉬난 필라이
프라모드 사르포트다르
데이비드 더블유. 오스보르네
고든 제이 다우
Original Assignee
다우 파마슈티컬 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다우 파마슈티컬 사이언시즈, 인코포레이티드 filed Critical 다우 파마슈티컬 사이언시즈, 인코포레이티드
Publication of KR20100063088A publication Critical patent/KR20100063088A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107006490A 2007-09-05 2008-07-30 서방성 아지스로마이신 고형 약형 Withdrawn KR20100063088A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96750407P 2007-09-05 2007-09-05
US60/967,504 2007-09-05
US12/002,417 2007-12-17
US12/002,417 US8124123B2 (en) 2007-09-05 2007-12-17 Controlled release azithromycin solid dosages forms

Publications (1)

Publication Number Publication Date
KR20100063088A true KR20100063088A (ko) 2010-06-10

Family

ID=40407900

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107006490A Withdrawn KR20100063088A (ko) 2007-09-05 2008-07-30 서방성 아지스로마이신 고형 약형
KR1020107006491A Withdrawn KR20100054842A (ko) 2007-09-05 2008-09-04 피부 질환의 치료를 위한 아지스로마이신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107006491A Withdrawn KR20100054842A (ko) 2007-09-05 2008-09-04 피부 질환의 치료를 위한 아지스로마이신

Country Status (12)

Country Link
US (2) US8124123B2 (https=)
EP (2) EP2197420A4 (https=)
JP (2) JP2010538062A (https=)
KR (2) KR20100063088A (https=)
CN (2) CN101861138A (https=)
AR (1) AR068368A1 (https=)
AU (2) AU2008295579A1 (https=)
BR (1) BRPI0816268A2 (https=)
CA (2) CA2697496A1 (https=)
RU (2) RU2010109358A (https=)
WO (2) WO2009032037A1 (https=)
ZA (2) ZA201001649B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
JP2011506319A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
JP7262118B2 (ja) * 2016-10-06 2023-04-21 オーバス セラピューティクス インコーポレイテッド 医薬組成物およびその使用
CN109875970B (zh) * 2019-01-08 2021-08-06 石家庄四药有限公司 阿奇霉素固体制剂及其制备方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
DE602004028023D1 (de) * 2003-08-29 2010-08-19 Lifecycle Pharma As Tacrolimus enthaltende feste dispersionen
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
CA2591923A1 (en) 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
CN101217944A (zh) * 2005-04-08 2008-07-09 艾博特公司 包含非诺贝酸和/或其盐的口服药物制剂
BRPI0617693A2 (pt) * 2005-11-09 2011-08-02 Dow Pharmaceutical Sciences azitromicina para o tratamento de rosácea granulomatosa
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne

Also Published As

Publication number Publication date
EP2197453A4 (en) 2010-10-20
US20090060994A1 (en) 2009-03-05
US20120121702A1 (en) 2012-05-17
CN101835475A (zh) 2010-09-15
JP2010538066A (ja) 2010-12-09
EP2197453A1 (en) 2010-06-23
US8124123B2 (en) 2012-02-28
AU2008295579A1 (en) 2009-03-12
JP2010538062A (ja) 2010-12-09
ZA201001649B (en) 2010-11-24
EP2197420A4 (en) 2010-10-20
RU2010109358A (ru) 2011-10-20
CA2697537A1 (en) 2009-03-12
CA2697496A1 (en) 2009-03-12
AU2008296903A1 (en) 2009-03-12
WO2009032268A1 (en) 2009-03-12
AR068368A1 (es) 2009-11-11
KR20100054842A (ko) 2010-05-25
BRPI0816268A2 (pt) 2017-08-22
CN101861138A (zh) 2010-10-13
WO2009032037A1 (en) 2009-03-12
ZA201001705B (en) 2010-12-29
RU2010109359A (ru) 2011-10-20
EP2197420A1 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
US8124123B2 (en) Controlled release azithromycin solid dosages forms
US20230011269A1 (en) Pharmaceutical composition comprising a potent inhibitor of urat1
US20110008426A1 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
IE56058B1 (en) New oral mopidamol preparations
AU2008288106A1 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
GB2414668A (en) Sustained release delivery system for tetracycline compounds
WO2021165316A1 (en) Pharmaceutical composition comprising dapagliflozin
EP1820506B1 (en) Dipyridamole extended-release formulations and process for preparing same
WO2004096182A1 (en) Extended release matrix tablets of carvedilol
CN112472679A (zh) 双释放片及其制备方法
TWI883162B (zh) 一種非布司他片
KR101925590B1 (ko) 개선된 생체이용률을 갖는 페노피브릭산 제제
WO2009027786A2 (en) Matrix dosage forms of varenicline
EP3331502B1 (en) Controlled release propiverine formulations
EP3796908B1 (en) Controlled release propiverine formulations
WO2024095137A1 (en) Pharmaceutical composition of empagliflozin and process thereof
EP1560568B1 (en) Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate
KR20250123715A (ko) 생체이용률이 개선된 닌테다닙을 포함하는 약학적 조성물
EA049514B1 (ru) Фармацевтическая композиция, содержащая дапаглифлозин
HK1104791B (en) Dipyridamole extended-release formulations and process for preparing same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100325

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid